nach oben

Erschienen in:

2014 | OriginalPaper | Buchkapitel

1. Maligne Tumoren der Mamma

verfasst von : Christian Schem, Walter Jonat, Nicolai Maass

Erschienen in: Praxisbuch Gynäkologische Onkologie

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

In dem Kapitel Maligne Tumoren der Mamma wird die Pathologie, Diagnostik und Therapie der Erkrankung umfassend beschrieben. Von der Klassifikation der Erkrankung, bis hin zu modernen OP-Techniken und der Planung der Therapie in Bezug auf die unterschiedlichen intrinsischen Subtypen des Mammakarzinoms bietet dieses Kapitel einen guten Überblick über den Goldstandard in der Behandlung. Darüber hinaus werden zukunftsweisende Behandlungsstrategien und Medikationen aus der aktuellen Diskussion und Wissenschaft wiedergegeben. Das Kapitel eignet sich nicht nur für das Studium, sondern stellt ebenso ein Nachschlagewerk für den Arzt bzw. die Ärztin in der Weiterbildung dar. Die Literatur wurde umfangreich aktualisiert und bietet somit die Möglichkeit in das tiefere Studium zu dieser Erkrankung einzusteigen.

Aberzk WJ, Siver B, Henderson IC, Cady B, Harris JR (1986) The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy. Cancer 58: 1214–1218 CrossRef

Adzersen KH, Gerhard I (2001) Phytoöstrogene und Brustkrebs – Senken Pflanzenöstrogene das Risiko? Geburtshilfe Frauenheilkd 61: 234–241

Aebi S, Gelber S, Lang I, Anderson S, Robidoux A, Martin M et al (2012) Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial. Cancer Res 72 (24 Suppl) 96s (Abstr. S3-2)

Armstrong K, Moye E, Wiliams S, Berlin J A, Reynolds E E (2007) Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians. Ann Intern Med 146: 516–526 CrossRef

ATAC Trialists Group (2008) Effect of anastrazole and tamoxifen as adjuvant treatment for early breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9: 45–53 CrossRef

Baselga J, Gelmon KA, Verma S et al. (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28: 1138–44 PubMedCrossRef

BIG 1-98 Collaborative Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353: 2747–2757

Bilchert-Toft M, Smola MG, CataliottiL, O’Higgins N (1997) Principles and guidelines for surgeons – management of symptomatic breast cancer. European Society of Surgical Oncology. Eur J Surg 23: 101–109 CrossRef

Blackwell KL, Burstein HJ, Storniolo AM et al. (2010) Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28: 1124–30 PubMedCrossRef

Bonnier P, Romain S, Dilhuydy JM et al. (1997) Influence of pregnancy on the outcome of breast cancer: a case-control study. Societe Francaise de Senologie et de Pathologie Mammaire Study Group. Int J Cancer 4: 720–727 CrossRef

Bratthauer GL, Tavassoli FA (2002) Lobular intraepithelial neoplasia: previously unexplored aspects assessed in 775 cases and their clincal implications. Virchows Arch 440: 134–138 PubMedCrossRef

Brown JE, Coleman RE (2003) Metastatic bone disease: developing strategies to optimize management. Am J Can 2: 269–281 CrossRef

Brufsky A, Rivera R, Hurvitz A et al. (2010) Progression-free survival in patient subgroups in RIBBON-2, a phase II trial of chemotherapy plus or minus bevacizumab for second-line treatment of Her2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 28 (Suppl) Abstr. 1021

Buchholz TA, Katz A, Strom EA et al. (2002) Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys 53: 880–888 PubMedCrossRef

Calabrese C, Distante V, Orzalesi L et al. (2001) Immediate reconstruction with mammaplasty in conservative breast cancer treatment: long-term results. Focus Rec Breast Cancer Surg Osp Ital Chir 7: 38–46

Coombes RC, Hall E, Gibson LJ et al. (2004) A randomized trial of exemestane after two years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350: 1081–1092 PubMedCrossRef

Coombes R, Kilburn L, Snowdown C (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup exemestane study): a randomised controlled trial. Lancet 369: 559–570 PubMedCrossRef

Dunne C, Burke JP, Morrow M, Kell MR (2009) Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol 27: 1615–20 PubMedCrossRef

Early Breast Cancer Trialists’ Collaborative Group (1995) Effects of radiotherapy and surgery in early breast cancer: an overview of the randomized trials. N Engl J Med 335: 1444–1455

Early Breast Cancer Trialists’ Collaborative Group (1996) Ovarian ablation in early breast cancer. Overview of randomized trials. Lancet 348: 1189–1198 CrossRef

Early Breast Cancer Trialists’ Collaborative Group (2000) Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials. Lancet 355: 1757–1770 CrossRef

Early Breast Cancer Trialists Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365: 1687–1717 CrossRef

Ellis MJ, Hayes DF, Lippmann ME (2000) Treatment of metastatic breast cancer. Cancer 2000: 749–797

Faverly DR, Burgers L, Bult P, Holland R (1994) Three dimensional imaging of mammary ductal carcinoma in clinical implications. Semin Diagn Pathol 11: 193–198 PubMed

Fisher B, Anderson S (1994) Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. World J Surg 18: 63–69 PubMedCrossRef

Fisher B, Wolmark N, Bauer M, Redmond C, Gebhardt M (1981) The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic and nodal status in carcinoma of the breast cancer. Surg Gynecol Obstet 152: 765–772 PubMed

Fisher B, Anderson S, Bryant J et al. (2002) Twenty-year follow-up a randomized trial comparing total mastectomy, lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347: 1233–1241 PubMedCrossRef

Fossati R, Confalonieri C, Torri V et al. (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31510 women. J Clin Oncol 16: 3439–3460 PubMed

Geyer, C, Forster J, Lindquist D et al. (2006) Lapatinib plus capecitabine for her2-positive advanced breast cancer. N Engl J Med 355: 2733–2743 PubMedCrossRef

Giuliano AE, Hunt KK, Ballman KV et al. (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305(6): 569–575. doi: 10.1001/jama.2011.90 PubMedCrossRef

Gnant M, Mlineritsch B, Stoeger H et al.; Austrian Breast and Colorectal Cancer Study Group (2011) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12(7): 631–641. doi: 10.1016/S1470-2045(11)70122-X. Epub 2011 Jun 5.

Goldhirsch A, Wood W, Gelber R et al. (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18: 1133–1144 PubMedCrossRef

Goss PE, Ingle JN, Martino S et al. (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen for early-stage breast cancer. N Engl J Med 349: 1793–1802 PubMedCrossRef

Guinee VF, Olsson H, Moller T et al. (1994) Effect of pregnancy on prognosis for young women with breast cancer. Lancet 343: 1587–1589 PubMedCrossRef

Haffty BG, Fischer D, Beinfield M, Mckhann C (1991) Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys 21: 293–298 PubMedCrossRef

Hartmann LC, Schaid DJ, Woods JE et al. (1999) Efficacy of bilateral prophylactic mastectomy in women with family history of breast cancer. N Engl J Med 340: 77–84 PubMedCrossRef

Henderson IC, Berry DA, Demetri GD et al. (2001) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21: 976–983 CrossRef

Hortobagyi GM, Ames FC, Buzdar AU et al. (1988) Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62: 2507 PubMedCrossRef

Hoskin PJ, Yarnold JR, Roos DR, Bentzen S (2001) Second Workshop on palliative radiotherapy and symptom control: radiotherapy for bone metastases. Clin Oncol 13: 88–90

Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. AWMF-Register-Nummer: 032–045OL. Kurzversion 3.0. Juli 2012

Jakesz R, Jonat W, Gnant M et al. (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrazole after 2 years’ adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366: 455–462 PubMedCrossRef

Kaufmann M, Costa SD, Scharl A (Hrsg) (2003) Die Gynäkologie. Springer, Berlin Heidelberg New York

Keck C, Tempfer C (2002) Hormonersatztherapie bei Frauen nach Brustkrebserkrankung. Geburtshilfe Frauenheilkd 62: 1053–1059 CrossRef

Keck C, Tempfer C (2003) Hormonsubstitution und Mammakarzinomscreening. Geburtshilfe Frauenheilkd 63: 999–1003 CrossRef

Klijn JG, Blamey RW, Boccardo F et al. (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19: 343–353 PubMed

Köchli OR, Sevin BU, Benz J, Petru E (1998) Gynäkologische Onkologie. Springer, Berlin Heidelberg New York CrossRef

Koscielny S, Tubiana M (1999) The link between local recurrence and distant metastases in breast cancer. Int J Radiat Oncol Biol Phys 43: 245–246 CrossRef

Kreipe HH (2012) Translationale Forschung und Diagnostik beim Mammakarzinom. Pathologe (Suppl 2) 33:282–290

Kroman N, Wohlfahrt J, Andersen KW, Mouridsen HT, Westergaard T, Melbye M (1997) Time since childbirth and prognosis in primary breast cancer: population based study. Int J Cancer 72: 720–727 CrossRef

Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. (2013) Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 14:609–618 PubMedCrossRef

Lagios MD, Westdahl PR, Margolin FR, Rose MR (1982) Ductal carcinoma in situ. Relationship or extent of noninvasive to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer 50: 1309–1314 PubMedCrossRef

Levine MN, Bramwell VH, Pritchard KI et al. (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trial Group. J Clin Oncol 16: 2651–2658 PubMed

LHRH-agonists in Early Breast Cancer Overview group (2007) Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: A meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369: 1711–1723 CrossRef

Miller K, Wang M, Gralow J et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastastic breast cancer. N Engl J Med 357: 2666–2676 PubMedCrossRef

Moebus V, Jackisch C, Lueck HJ et al. (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 28: 2874–2880 PubMedCrossRef

Niemeyer M, Paepke S, Schmied R et al. (2009) Subcutaneous mastectomy including skin conservation of the nipple areola complex: broadening the indications. Cancer Res. 69 (Suppl) Abstr. 3107

Noguchi M, Fukushima W, Ohta N et al. (1992) Oncological aspects of immediate breast reconstruction im mastectomy patients. J Surg Oncol 50: 241–246 PubMedCrossRef

O’Shaughnessy J, Dieras V, Glaspy J, et al. (2009) Comparison of subgroup analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer. Cancer Res 69 (Suppl) Abstr. 207

Paradiso A, Schittuli F, Cellamare G et al. (2001) Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferation, node-negative breast cancer. J Clin Oncol 19: 3929–3937 PubMed

Rebbeck TR, Levin AM, Eisen A et al. (1999) Breast cancer risk after bilateral prophylactic oophorectomy BRCA1 mutation carriers. J Natl Cancer Inst 91: 1475–1479 PubMedCrossRef

Rebbeck TR, Lynch HT, Neuhausen SL et al. (2002) Prevention and observation of surgical end points study group. N Engl J Med 346: 1616–1622 PubMedCrossRef

Robertson JF, Osborne CK, Howell A et al. (2003) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98: 229–238 PubMedCrossRef

Schrag D, Kuntz KM, Garber JE, Weeks JC (1997) Decision analysis – effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 and BRCA2 mutations. N Engl J Med 336: 1465–1471 PubMedCrossRef

Schwartz GF, Solin LJ, Olivotto IA, Ernster VL, Pressmann PI (2000) Consensus Conference on the Treatment of In Situ Ductal Carcinoma in the Breast, April 22–25, 1999. Cancer 15: 946–954

Silverstein MJ, Craig PH, Lagios MD et al. (1996) Developing a prognostic index for ductal carcinoma in situ of breast. Cancer 78: 1138–1140 PubMedCrossRef

Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 3444: 783–792 CrossRef

Smith I, Procter M, Gelber R et al. (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomized controlled trial. Lancet 369: 29–36 PubMedCrossRef

Solin L, Orel S, Hwang W et al (2008) Relationship of breast magnetic resonance imaging after breast conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol 26: 386–391 PubMedCrossRef

Stadtmauer EA, O’Neill A, Goldstein LJ et al. (2000) Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med 342: 1069–1076 PubMedCrossRef

The ATAC Trialists Group (2003) Anastozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: results of the ATAC Trial Efficacy and Safety Update Analysis. Cancer 98: 1802–1810 CrossRef

Thürlimann B (2005) BIG-1–98. A prospective randomized phase III study to evaluate letrozol as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast 14: 4 CrossRef

Tran NV, Chang DW, Gupta A, Kroll SS, Robb GL (2001) Comparison of immediate and delayed free TRAM flap breast reconstruction in patients receiving postmastectomy radiation therapy. Plast Reconstr Surg 108: 78–82 PubMedCrossRef

Tutt A, Robson M, Garber J et al. (2010) Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof of concept trial. Lancet 376: 235–244 PubMedCrossRef

Vandeweyer E, Deraemaecker R, Nogaret JM, Hertens D (2000) Institution immediate breast reconstruction with implants and adjuvant chemotherapy: a good option? Eur J Cancer [Suppl 5] 36: 59

Vandeweyer E, Hertens D, Nogaret JM, Deraemaecker R (2001) Immediate breast reconstruction with saline filled implants: no Interference with the oncologic outcome? Plast Reconstr Surg 107: 1409–1412 PubMedCrossRef

Van Teinhoven G, Voogd AC, Peterse JL et al. (1999) Prognosis after treatment for loco-regional recurrence after mastectomy and breast-conserving therapy in two randomised studies (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish BREast Cancer Cooperative Group. Eur J Cancer 35: 32–38 CrossRef

Veronesi U, Cascinelli N, Mariani L et al. (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347: 1277–1232 CrossRef

Veronesi U, Paganelli G, Viale G et al. (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349: 546–553 PubMedCrossRef

Voogd AC, Nielsen M, Peterse JL et al. (2001) Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 19: 1688–1697 PubMed

Whelan TJ, Julian J, Wright J, Jadad AR, Levine ML (2000) Does locoregional radiation therapy improve survival in breast cancer? A metaanalysis. J Clin Oncol 18: 1220–1229 PubMed

Titel: Maligne Tumoren der Mamma
verfasst von: Christian Schem
Walter Jonat
Nicolai Maass
Verlag: Springer Berlin Heidelberg
Buch: Praxisbuch Gynäkologische Onkologie
Print ISBN: 978-3-662-43468-0

Electronic ISBN: 978-3-662-43469-7

Copyright-Jahr: 2014
DOI: https://doi.org/10.1007/978-3-662-43469-7_1

Neu im Fachgebiet Gynäkologie und Geburtshilfe

31.03.2023 | Abrechnung | Nachrichten

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Hauptrubriken

Service

Fachgebiete

Themen

Sammlungen

Springer Medizin

1. Maligne Tumoren der Mamma

Zusammenfassung

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Quartalswechsel: Volles Honorar in der Pädiatrie, Telefon-AU läuft aus

EBM-Beschluss: Kassen beteiligen sich an horrenden Stromkosten

Phase-3-Studien: Wirksamere Erstlinientherapie bei Endometrium-Ca.

Hohe Burnout-Rate unter Klinikfachärzten

Update Gynäkologie

Hauptrubriken

Service

Fachgebiete

Themen

Sammlungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Quartalswechsel: Volles Honorar in der Pädiatrie, Telefon-AU läuft aus

EBM-Beschluss: Kassen beteiligen sich an horrenden Stromkosten

Phase-3-Studien: Wirksamere Erstlinientherapie bei Endometrium-Ca.

Hohe Burnout-Rate unter Klinikfachärzten

Update Gynäkologie